The document calls for papers for a special issue of the Canadian Respiratory Journal on advanced monoclonal antibodies for asthma. It discusses how monoclonal antibodies work in treating asthma by altering inflammatory proteins and redox metabolites. It invites original research and review articles on targeted therapeutics for severe asthma using monoclonal antibodies against IL5, IL17, VCAM1, mepolizumab, reslizumab, and IL13. Potential topics also include real-life data and effects on comorbidities of monoclonal antibody therapy in asthma patients.

1. Canadian Respiratory Journal
Special Issue on
Advanced Monoclonal Antibodies for Asthma
CALL FOR PAPERSThe mechanism of action of monoclonal antibodies in the treatment of asthma is
believed to be multifactorial and includes effects mediated through altered pro-
duction of redox metabolites and regulation of production of known inflammatory
proteins.
We invite investigators to contribute original research articles as well as review
articles that will stimulate continuing efforts to leverage biomarkers to improve
accuracy, discover the molecular pathology underlying allergic disorders, develop
strategies to treat these conditions, and evaluate the outcomes.
Potential topics include but are not limited to the following:
Targeted therapeutics for severe refractory asthma: monoclonal antibodies
Safety of monoclonal antibodies in asthma such as anti-IL5, anti-IL17,
anti-VCAM 1, Mepolizumab, Reslizumab, and anti-IL13
Real life data in allergic asthma patients on monoclonal antibody therapy
such as anti-IL5, anti-IL17, anti-VCAM 1, Mepolizumab, Reslizumab, and
anti-IL13
Effects of monoclonal antibodies with comorbid situations in asthma
Monoclonal antibody usage in pregnant asthmatics
Authors can submit their manuscripts through the Manuscript Tracking System at
http://mts.hindawi.com/submit/journals/crj/amaa/.
Lead Guest Editor
Arzu D. Yalcin, Antalya Training and
Research Hospital, Antalya, Turkey
adidyal@yahoo.com
Guest Editors
Tse W. Chang, Academia Sinica
Genomics Research Center, Taipei,
Taiwan
twchang@gate.sinica.edu.tw
Felix Herth, University of Heidelberg,
Heidelberg, Germany
felix.herth@med.uni-heidelberg.de
Jaap Wieling, Biosana Pharma,
Haarlem, Netherlands
jaap.wieling@biosanapharma.com
Basil Elnazir, Al Jalila Childrens
Speciality Hospital, Dubai, UAE
belnazir@dha.gov.ae
Manuscript Due
Friday, 23 December 2016
First Round of Reviews
Friday, 17 March 2017
Publication Date
Friday, 12 May 2017